11

12

13

14

15

16

17

18

19

## PROPOSED PROVISIONS FOR HOUSE AMENDMENT TO SENATE AMENDMENT TO H.R. 4386

Add at the end of the Senate amendment the following section:

## 1 SEC. 3. HUMAN PAPILLOMAVIRUS; ACTIVITIES OF CENTERS

| 2 | FOR DISEASE CONTROL    | AND PREVENTION. |
|---|------------------------|-----------------|
| _ | I OIL DINDING CONTINUE |                 |

3 Part B of title III of the Public Health Service Act

4 (42 U.S.C. 243 et seq.) is amended by inserting before

5 section 318 the following section:

6 "HUMAN PAPILLOMAVIRUS

7 "Sec. 317P. (a) Surveillance.—

8 "(1) In General.—The Secretary, acting

9 through the Director of the Centers for Disease

10 Control and Prevention, shall—

"(A) enter into cooperative agreements with States and other entities to conduct sentinel surveillance or other special studies that would determine the prevalence in various age groups and populations of specific types of human papillomavirus (referred to in this section as 'HPV') in different sites in various re-

gions of the United States, through collection of

special specimens for HPV using a variety of



| 1  | laboratory-based testing and diagnostic tools;       |
|----|--|
| 2  | and  |
| 3  | "(B) develop and analyze data from the               |
| 4  | HPV sentinel surveillance system described in        |
| 5  | subparagraph (A).                                    |
| 6  | "(2) Report.—The Secretary shall make a              |
| 7  | progress report to the Congress with respect to      |
| 8  | paragraph (1) not later than one year after the ef-  |
| 9  | fective date of this section.                        |
| 10 | "(b) Prevention Activities; Education Pro-           |
| 11 | GRAM.—   |
| 12 | "(1) In General.—The Secretary, acting               |
| 13 | through the Director of the Centers for Disease      |
| 14 | Control and Prevention, shall conduct prevention re- |
| 15 | search on HPV, including—                            |
| 16 | "(A) behavioral and other research on the            |
| 17 | impact of HPV-related diagnoses on individuals;      |
| 18 | "(B) formative research to assist with the           |
| 19 | development of educational messages and infor-       |
| 20 | mation for the public, for patients, and for their   |
| 21 | partners about HPV;                                  |
| 22 | "(C) surveys of physician and public                 |
| 23 | knowledge, attitudes, and practices about gen-       |
| 24 | ital HPV infection: and                              |



| 1  | "(D) upon the completion of and based on                 |
|----|--|
| 2  | the findings under subparagraphs (A) through             |
| 3  | (C), develop and disseminate educational mate-           |
| 4  | rials for the public and health care providers re-       |
| 5  | garding HPV and its impact and prevention.               |
| 6  | "(2) Report; final proposal.—The Sec-                    |
| 7  | retary shall make a progress report to the Congress      |
| 8  | with respect to paragraph (1) not later than one         |
| 9  | year after the effective date of this section, and shall |
| 10 | develop a final proposal not later than two years        |
| 11 | after such effective date, including a detailed sum-     |
| 12 | mary of the significant findings and problems and        |
| 13 | the best strategies to prevent future infections.        |
| 14 | "(c) HPV Education and Prevention.—                      |
| 15 | "(1) In General.—The Secretary shall pre-                |
| 16 | pare and distribute educational materials for health     |
| 17 | care providers and the public that include informa-      |
| 18 | tion on all sexually transmitted diseases, including     |
| 19 | HPV and HIV infection. Such materials shall              |
| 20 | address—   |
| 21 | "(A) modes of transmission;                              |
| 22 | "(B) consequences of infection, including                |
| 23 | the link between HPV and cervical cancer;                |
| 24 | "(C) the effectiveness or lack of effective-             |
| 25 | ness of both condoms and abstinence in pre-              |



| 1  | venting infection with sexually transmitted dis-        |
|----|---|
| 2  | eases, including HPV; and                               |
| 3  | "(D) the importance of regular pap                      |
| 4  | smears, HIV testing, and sexually-transmitted-          |
| 5  | disease screening for early intervention pur-           |
| 6  | poses.  |
| 7  | "(2) Medically accurate information.—                   |
| 8  | Educational materials under paragraph (1), and all      |
| 9  | other relevant educational and prevention materials     |
| 10 | prepared for the public and health care providers by    |
| 11 | the Secretary (including materials prepared through     |
| 12 | the Food and Drug Administration, the Centers for       |
| 13 | Disease Control and Prevention, and the Health Re-      |
| 14 | sources and Services Administration), or by other       |
| 15 | Federal departments or agencies, or by contractors,     |
| 16 | grantees, or subgrantees thereof, that are specifically |
| 17 | designed to address sexually transmitted diseases or    |
| 18 | condoms shall contain medically accurate informa-       |
| 19 | tion regarding the effectiveness or lack of effective-  |
| 20 | ness of condoms in preventing HPV infection, HIV        |
| 21 | infection, and other sexually transmitted diseases.     |
| 22 | Such requirement only applies to materials mass         |
| 23 | produced for the public and health care providers,      |
| 24 | and not to routine communications.".                    |



| 1  | SEC. 4. LABELING OF CONDOMS WITH RESPECT TO HUMAN           |
|----|---|
| 2  | PAPILLOMAVIRUS AND OTHER SEXUALLY                           |
| 3  | TRANSMITTED DISEASES.                                       |
| 4  | The Secretary of Health and Human Services shall            |
| 5  | reexamine existing condom labels that are authorized pur-   |
| 6  | suant to the Federal Food, Drug, and Cosmetic Act to        |
| 7  | ensure that the labels are medically accurate and not mis-  |
| 8  | leading regarding the overall effectiveness and lack of ef- |
| 9  | fectiveness of condoms in preventing sexually transmitted   |
| 10 | diseases, including HIV infection and infection with the    |
| 11 | human papillomavirus.                                       |

